Randomized trial · people
Exenatide: no significant drop in heart events vs placebo in EXSCEL
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a large trial, once-weekly exenatide did not raise major heart events in type 2 diabetes, but it also did not significantly lower them compared with placebo.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 14752
- Published
- 2017
- Journal
- N Engl J Med
What they tested
The team tested whether adding once-weekly exenatide to usual care was safe for the heart in type 2 diabetes, and whether it cut major heart events.
How the study was done
A randomized, placebo-controlled trial in 14,752 people with type 2 diabetes, 73.1% of whom already had cardiovascular disease. They got 2 mg extended-release exenatide or a matching placebo (dummy) shot once a week and were followed for a median of 3.2 years.

What they found
The main outcome was a first heart attack, stroke or death from heart causes. It happened in 839 of 7356 people (11.4%) on exenatide and 905 of 7396 people (12.2%) on placebo, a hazard ratio (relative risk over time) of 0.91 (95% CI 0.83 to 1.00). Exenatide met the bar for being no worse than placebo on safety (P<0.001), but not for being better (P=0.06). Heart deaths, heart attacks, strokes, heart failure hospital stays, pancreatitis, pancreatic cancer, medullary thyroid cancer and serious side effects did not differ significantly between groups.
What it doesn’t show
The trial tested only the 2 mg once-weekly form in people with type 2 diabetes, so it does not speak to other doses or to people without diabetes. It was funded by Amylin Pharmaceuticals.
The paper
Holman et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017.
The compound
More studies on Exenatide
- Exenatide: no cognitive benefit in mild cognitive impairmentRandomized trial · people · 2024
- Exenatide: lower intracranial pressure in IIH over 12 weeksRandomized trial · people · 2023
- Exenatide did not cut heavy drinking days in alcohol use disorderRandomized trial · people · 2022
- Exenatide: 29.2% spontaneous pregnancy vs 14.7% on metformin in PCOSRandomized trial · people · 2022
- Exenatide plus dapagliflozin: UACR fell 39.6% vs 11.0% on placeboRandomized trial · people · 2021
- Exenatide, alone or with dapagliflozin, improved blood sugar in PCOSRandomized trial · people · 2021
- Every study on Exenatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.